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Abstract
Objective: To examine the ability of machine learning methods to predict upgrading of Gleason score on confirmatory magnetic resonance imaging-guided targeted biopsy (MRI-TB) of the prostate in candidates for active surveillance.
Subjects and methods: Our database included 592 patients who received prostate multiparametric magnetic resonance imaging in the
evaluation for active surveillance. Upgrading to significant prostate cancer on MRI-TB was defined as upgrading to G 3+4 (definition 1 DF1) and 4+3 (DF2). Machine learning classifiers were applied on both classification problems DF1 and DF2.
Results: Univariate analysis showed that older age and the number of positive cores on pre-MRI-TB were positively correlated with
upgrading by DF1 (P-value ≤ 0.05). Upgrading by DF2 was positively correlated with age and the number of positive cores and negatively
correlated with body mass index. For upgrading prediction, the AdaBoost model was highly predictive of upgrading by DF1 (AUC 0.952),
while for prediction of upgrading by DF2, the Random Forest model had a lower but excellent prediction performance (AUC 0.947).
Conclusion: We show that machine learning has the potential to be integrated in future diagnostic assessments for patients eligible for
AS. Training our models on larger multi-institutional databases is needed to confirm our results and improve the accuracy of these models’
prediction. Ó 2022 Elsevier Inc. All rights reserved.
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1. Introduction
The American Cancer Society estimates that, in 2021,
there will be 248,530 new prostate cancer (CaP) cases diagnosed and 34,130 CaP deaths in the United States [1].
Active surveillance (AS) represented a paradigm shift in
the management of CaP. The use of AS increased from
22% in 2004 to 2005 to 50% in 2014 to 2015 for patients
with a Gleason score of 6 or below and from 9% in 2004 to
2005 to 13% in 2014 to 2015 for patients with a Gleason
Source of funding: None.
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score of 7 or above [2]. Radiation therapy and surgery are 2
other options for treating PCa, but they are both associated
with long lasting adverse effects on patients’ urinary and
sexual quality of life [3]. It has been shown that AS maintains excellent quality of life for PCa patients and is associated with excellent overall survival in well-designed
prospective studies [4].
Recognizing the clinical need for accurate characterization of PCa in patients interested in AS, the scientific community has developed multiple biomarkers and imaging
technologies to predict the upgrading of CaP diagnosed on
prostate biopsy on final post-prostatectomy pathology. For
this purpose, magnetic resonance imaging (MRI) and MRI
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based targeted biopsy (MRI-TB) emerged as 1 method of
accurately characterizing the grade of CaP in patients who
are candidates for AS [5]. However, MRI-TB of the prostate is an invasive procedure, and MRI of the prostate may
not be available to some patients for reasons of comorbidities, patient weight restrictions, claustrophobia, and limited
access [6,7]. Here, we report a machine learning-based
model solution to this challenge. In this model, we used disease characteristics identified from systematic ultrasoundguided prostate biopsy and patient clinical features to predict Gleason score upgrading on MRI-TB of the prostate
that can be directly used to guide treatment in clinical settings. This model, if validated, can be used in patients unfit,
unwilling, or unable to access MRI-TB to counsel them on
the safety of active surveillance of PCa.
2. Subjects and methods
After institutional review board approval, we performed
a retrospective review of MRI-TB performed in patients
managed with AS from October 2015 to February 2018 at a
large health care organization. All MRI-transrectal ultrasound fusion-guided biopsies were performed by a single
urologist with several years of experience in MRI-transrectal ultrasound targeted biopsy using the DynaCAD MRItransrectal ultrasound fusion biopsy system UroNav
(Invivo, Gainseville, FL). The biopsies were conducted
using local anesthetic in the outpatient setting. Three target
biopsy cores were taken from each lesion and were immediately followed by a 12-core systematic biopsy where 1 core
was taken from each of the 12 sectors. Biopsies were scored
by a fellowship-trained genitourinary pathologist.
Our database of 592 patients contained BMI, ethnicity,
age, digital rectal examination results, PSA density
(PSAD), number of pre-MRI biopsies, and number of positive cores, and results of MRI targeted biopsy. The workflow of our model is illustrated in Fig. 1. For this research,
we applied our model on upgrading definition 1 (DF1) and
upgrading definition 2 (DF2). DF1 was the detection of PCa
GG > 3+3 on MRI-TB. DF2 was the detection of PCa GG
> 3+4 on MRI-TB. We imputed the missing values with the
average of the corresponding feature for each class. Initially, labeling the samples by upgrading vs. non-upgrading
on MRI-TB led to a non-balance class prediction model
biased toward the majority class. Therefore, preprocessing
techniques were utilized for both datasets to handle the
class imbalance issue and achieve higher prediction accuracy. For the first prediction model (DF1 vs. non-DF1), 2
techniques were applied; the synthetic minority over-sampling technique (SMOTE) was applied first to generate synthetic samples from the distribution of the minority class.
Then, a simple random sampling with replacement was
applied to produce a new subset containing equal DF1 and
non-DF1 [8]. For the second prediction model (DF2 vs.
non-DF2), SMOTE over-sampling technique is not enough
due to the big difference between the number of samples

between the majority and the minority classes. So both
over-sampling and under-sampling techniques were used
by selecting balanced ensembles with random samples
from both classes. The classifier runs on the balanced
ensembles that have the same number of samples in each
class [9].
Overfitting is the main challenge in training the machine
learning model. The model is trained on 90% of the data
and tested on the remaining 10% each time to overcome
overfitting. Then this process is repeated another 9 times,
where the model test on another 10% each time. In the end,
the model will be testing on the whole samples (100%)
without using them in training (at each step ’’Fold’’). We
tested different types of classifiers (Support Vector
Machine, NaiveBayes, RandomForest, Bagging, and AdaBoostM1) via the standard 10-fold cross-validation experiments. An exhaustive search determined the parameters
such as iteration number, base classifier, weight threshold,
maximum depth of tree, and number of features. AdaBoost
classifier and random forest classifiers achieved the best
results DF1 dataset and DF2 dataset, respectively. In the
first prediction model, AdaBoost classifier was used to classify DF1 vs. non-DF1 [10]. The balanced dataset was classified using 10-fold cross-validation; at each time in the loop,
the AdaBoost classifier will take different samples from the
one which is used in the previous steps. AdaBoost algorithm is a Boosting technique used as an Ensemble Method
that combines multiple weak learners into a strong one.
Weak learners are trained sequentially with weighted
instances, where weights are updated and re-assigned each
iteration, so higher weights are applied to incorrectly classified instances. AdaBoost HðxÞ can be denoted as the following:
!
T
X
H ðxÞ ¼ sign
/ t h t ð xÞ
t¼1

D1 ðiÞ ¼ 1=m
Dtþ1 ðiÞ ¼

Dt ðiÞ expð / t yi ht ðxi ÞÞ
Zt

Where:
xi and yi represent the instances and their labels.
D1 ðiÞ is the initial weights
Dtþ1 ðiÞ is the updated weights.
Zt is a normalization factor.
/ t is the weight updating parameter.
The second prediction model DF2 was built using a random forest classifier [11]. DF2 samples were tripled, and
then 3 different ensembles were made by dividing the nonDF2 samples into 3 equal ensembles with different samples.
Each ensemble of the non-DF2 matches the DF2 number of
samples to have 3 balanced classification models. In each
model we use 10-fold cross-validation with a random forest
classifier to predict DF2 vs. non-DF2 samples.
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Fig. 1. The workflow of the machine learning model to predict upgrading of Gleason score on confirmatory magnetic resonance imaging guided targeted
biopsy (MRI-TB) of the prostate in candidates for active surveillance.

Random forest prioritizes the features based on the
GINI-index values of the features, where the 1 of higher
value is the root of the tree and the next levels are for the
less value, down to the least important features at the bottom of the tree. GINI-Index values areP
cdenoted as the following equation:GINI  Index ¼ 1  ðpi Þ2
Where pi represents the frequencyi¼1of the samples in
class i, c represents the number of classes. Over/random
sampling was applied to the whole dataset before we moved
to the classification step.
The prediction performance was evaluated by Receiver
Operating Characteristics curve (ROC), Accuracy, Precision,
Recall, F-Measure, and Matthews Correlation coefficient.

[12] We also provided the GINI-index values for clinical features to help readers verify that feature of importance in
other types of models (logistic regression) are as well important in our model.
2.1. MRI acquisition and interpretation
All patients were imaged on 1 of 2 MRI systems: a GE
Discovery 750 3.0-Tesla (GE Health care, Waukesha, WI),
using a 32-channel torso phased array coil or a Philips
Ingenia 3.0-Tesla (Philips Health care, Best, the Netherlands)
using a 32-element anterior torso phased array coil coupled
with an integrated posterior 20 element array in the tabletop.
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All patients underwent a highly similar imaging protocol
consisting of: large field of view (FOV) (32 cm or greater)
2-dimensional fast spin-echo T2-weighted images with fat
suppression, and 3-dimensional T1 gradient-echo with
Dixon fat-water separation (fat, water, in-phase, and out-ofphase reconstructions); small FOV (18 cm) fast spin-echo
T2 images of the prostate in the axial, sagittal and coronal
planes; axial diffusion weighted images in small FOV (Philips, 18 cm) and larger FOV (GE, 30 cm); small (22 cm)
FOV bolus intravenous gadolinium chelate dynamic contrast enhanced T1 gradient-echo series (20 serial post-contrast phases, temporal resolution <10 seconds); and a final
large FOV pelvic post-contrast T1 gradient-echo Dixon
(water reconstruction) series. These studies were done without endorectal coil. Examinations were interpreted and analyzed using DynaCAD (InVivo, Gainesville, FL) by a
single radiology group and followed PI-RADS v2 algorithms.
3. Results

respectively. The Area Under the Receiver Operating Characteristics Curve (AUC) was also high (95.2% for DF1 and
94.7% for DF2). The AUC and Area Under the PrecisionRecall Curve were calculated and plotted to utilize their
validity in an unbalanced dataset for further evaluation.
Fig. 1 illustrates the evaluation of DF1 model performance.
To determine which clinical feature plays a crucial role
in predicting upgrading of Gleason score, we calculated the
feature importance through GINI-Index values in random
forest. We found that PSAD is the most important, and digital rectal examination (DRE) is the least important, as
shown in Fig. 2.
To thoroughly evaluate each feature’s effect on the model’s accuracy, we also run ablation tests (test different combinations of features, e.g., leave 1 out in each test). The
PSA density feature came up as the most critical feature.
The Age feature and BMI showed a small difference
between them. The rest of the features had little importance
compared to the first 3 features (Table 2).
4. Discussion

Of patients who underwent MRI-TB (n = 592), 33.6%
were upgraded by DF1 and DF2 upgraded 9.7%. Univariate
analysis showed that older age and the number of positive
cores on pre-MRI biopsy were positively correlated with
upgrade by DF1 (P-value ≤ 0.05). Upgrade by DF2 was
positively correlated with age and number of positive cores
and negatively correlated with BMI. Baseline data used in
Machine learning-based prediction on targeted biopsy in
patients eligible for active surveillance are shown in
Table 1.
Our model has achieved high performance in each statistical measurement including accuracy of 94.3% and 88.1%,
precision of 94.6% and 88.0%, and recall of 94.3% and
88.1% for the DF1 (AdaBoost) and DF2 (random forest)
Table 1
Baseline data used in Machine learning-based prediction on targeted
biopsy in patients eligible for active surveillance.
Values
Mean § SD Age (RANGE)
Mean § SD (ng/mL) PSA (RANGE)
Mean § SD (mL) prostate volume (RANGE)
Mean § SD (months) Interval from previous
biopsy (RANGE)
Ethnicity = African American (%)
Ethnicity = White (%)
Ethnicity = Other (%)
Percent Abnormal DRE
Final Pathology = Benign (%)
Final Pathology = 3 + 3 (%)
Final Pathology = 3 + 4 (%)
Final Pathology = 4 + 3 (%)
Final Pathology = 4 + 4 (%)
Mean § SD Number of positive cores on
immediate pre-MRI-TB systematic biopsy
(range)

65.0 § 7.0 (49−83)
7.8 § 6.0 (0.6−61.3)
57.5 § 33.4 (15−195)
28.7 § 15.2 (1−132)
24.20%
60.00%
15.80%
30.60%
24.30%
42.50%
23.90%
8.60%
0.74%
1.9 § 2.9 (0−6)

We found that machine learning provided highly predictive models of upgrading after MRI-TB, which our ROC of
>94% reflected. Machine learning methods are good at constructing models on a complex or non-linear dataset, and
random forest applies the strategy of training on different
parts of the dataset and averaging multiple decision trees to
reduce the variance and avoid overfitting; thus, tree-based
methods, especially random forest, are more suitable for
such problems.[11] Our work provides an attempt to integrate cost-effective clinical variables with new analysis
methods to answer clinical questions instead of employing
more expensive predictors such as advanced imaging or
biomarkers.
There have been many attempts at developing biomarkers to select patients for active surveillance; however,
in many cases, the application of the biomarker in clinical
practice was limited by considerations of cost, feasibility,
and accuracy. One such biomarker is the 17-gene Oncotype
DX Genomic Prostate Score (GPS) test that was promoted
as a predictor of upgrading in patients with low-risk CaP
treated with immediate surgery. Lin et al. evaluated the
GPS test as a predictor of outcomes in a multicenter active
surveillance cohort where diagnostic biopsy tissue was
obtained from men enrolled at 8 sites in the Canary Prostate
Active Surveillance Study [13]. The primary endpoint was
adverse pathology (AP) (Gleason Grade Group [GG] ≥3,
≥pT3a) in men who underwent radical prostatectomy after
initial surveillance. The GPS results were obtained for 432
men (median follow-up, 4.6 years). GPS was not predictive
of AP when the authors adjusted for prostate-specific antigen density, and no association was observed between GPS
and subsequent biopsy upgrade (P = 0.48). The authors concluded that adding GPS to a model containing PSA density
and diagnostic Gleason grade did not significantly improve
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Fig. 2. The importance of the clinical features calculated using random forest.

stratification of risk for AP over the clinical variables alone.
We used diagnostic Gleason grade and PSA density in our
modeling and used them to predict upgrading on biopsy
accurately. Their results support clinical variables as effective predictors of upgrading and a good proxy of biology at
the molecular level.
Along the same lines, An American Society of Clinical
Oncology multidisciplinary expert panel, with representatives from the European Association of Urology, American
Urological Association, and the College of American Pathologists, conducted a systematic literature review of localized CaP biomarker studies between January 2013 and
January 2019 [14]. Of 555 studies identified by the panel,
77 were selected for inclusion, plus 32 additional references
selected by the Expert Panel. The panel highlighted Oncotype Dx Prostate, Prolaris, Decipher, Decipher PORTOS,
and ProMark in their analysis and identified a paucity of

Table 2
Results of the ablation tests to evaluate effects of different feature on
machine-learning based prediction of adverse pathology on magnetic resonance imaging targeted biopsy of the prostate.
Features

Accuracy

All features
BMI Out
Age Out
PSA Out
DRE Out
Number of positive cores in immediate pre MRI-TB
systematic biopsy Out
Number of pre- MRI-TB systematic biopsy Out

94.3
92.68
88.61
87.8
94.3
95.12
95.12

prospective studies assessing short- and long-term outcomes of patients when these markers are integrated into
clinical decision making. The panel then concluded that tissue-based molecular biomarkers are not recommended for
routine use and that they may improve risk stratification
only when added to standard clinical parameters. This panel’s guidelines support our approach to retooling available
clinical parameters using new analysis methods to predict
upgrading. Nevertheless, genomic markers continue to
have a yet to be explored potential for future integration in
machine learning- based predictive models to further
increase their predictive accuracy
We used clinical variables and machine learning to predict upgrading on MRI-TB of the prostate in patients who
are candidates for active surveillance. Through well
designed research, MRI-targeted biopsy was found to detect
significantly more grade progressions in active surveillance
patients compared to systematic biopsy providing compelling evidence that prostate MRI and MRI-TB should be
included in current active surveillance protocols [5]. However, MRI of the prostate is not accessible to many patients
due to difficulty contacting patients and insurance denials,
and African-American patients are disproportionately
affected by barriers to MRI of the prostate in the course of
Active surveillance [6,7]. Modeling clinical variables with
advanced methods such as machine learning could allow us
to use lessons learned from well-funded studies involving
advanced imaging technologies to manage patients in
resource-limited environments with limited access to these
technologies.
This study has limitations. One limitation is missing values. To impute the missing values, we replaced them with
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the average of the corresponding feature for each class,
which may introduce biases, and intensify the batch effects
among cohorts and complexity among features. Having
missing values in the dataset should be a strong reason why
linear, logistic regression, and Cox regression fail to generate highly predictive models. A more intact dataset should
generate more precise models. In addition, machine learning models mainly focus on prediction accuracy as a performance metric because it is sometime hard to explain the
process of prediction. Therefore, machine learning, is commonly described as black-box models. To overcome this
limitation in our analysis, provided the GINI-index values
for clinical feature to enable clinicians to know what clinical feature is the model using to make predictions so as to
give them insights into how this model is working and if
the model is classifying patients into different classes
(DF1 vs. DF2) for the right reasons.
Overall, our research shows that machine learning has
the potential to be integrated in future diagnostic assessments for patients eligible for AS. Training our models on
larger multi-institutional databases is needed to confirm our
results and improve the accuracy of these models’ prediction.
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